Asset profile
Samuraciclib
Small molecule
Evidence outlook · lead readout
NCT05963984 · Metastatic Breast Cancer, Locally Advanced Breast Cancer, Breast Cancer
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT05963984: The study was randomized across two samuraciclib-plus-fulvestrant arms and a fulvestrant-only comparator, but it was open-label and relatively small, with 60 participants overall. Its primary endpoint was a RECIST-based clinical benefit response, but results have not been posted, so whether the endpoint was met is unknown.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
December 2026 (1)
What to watch
Research analysis
Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.
Sign in to access Research2029 (1)
May 2029 (1)
What to watch
Research analysis
Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.
Sign in to access ResearchAll registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.